Vildagliptin and Omarigliptin Differentially Bind to DPP-4 Homodimers and Modulate Osteoclast-Mediated Bone Resorption. [PDF]
Compr PhysiolVildagliptin and omarigliptin, dipeptidyl peptidase‐4 (DPP‐4) inhibitors, have differential effects on bone cells. Although vildagliptin improved the bone microstructure of high‐fat diet‐fed rats, it was unable to downregulate osteoclastogenesis or the expression of key osteoclast transcripts.
Aeimlapa R +11 more
europepmc +2 more sources
Preclinical Modeling and Simulation to Explore the Tissue/Plasma Exposure and Pharmacodynamic Effect of Vildagliptin in Diabetes Treatment. [PDF]
CPT Pharmacometrics Syst PharmacolABSTRACT Vildagliptin (VDG) is a dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor used for type 2 diabetes (T2DM) treatment. Viewing to improve VDG treatment, a population pharmacokinetic (popPK) model was built to describe drug plasma, free liver and muscle concentrations determined by microdialysis in healthy and diabetic animals following 50 mg/kg i.v ...
Dias BB, Olivo LB, de Araújo BV.
europepmc +2 more sources
Molecules, 2021 During forced degradation, the intrinsic stability of active pharmaceutical ingredients (APIs) could be determined and possible impurities that would occur during the shelf life of the drug substance or the drug product could be estimated.
Anna Gumieniczek +4 more
doaj +1 more source
Nanofibrous Vildagliptin/PLGA Membranes Accelerate Diabetic Wound Healing by Angiogenesis
Pharmaceuticals, 2022 The inhibition of dipeptidyl peptidase-4 (DPP4) significantly enhances the wound closure rate in diabetic patients with chronic foot ulcers. DPP4 inhibitors are only prescribed for enteral, but topical administration, if feasible, to a wound would have ...
Chen-Hung Lee +5 more
doaj +1 more source
The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes [PDF]
Diabetes & Metabolism Journal, 2014 BackgroundWe evaluated the effects of two dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and vildagliptin, on metabolic parameters in patients with type 2 diabetes mellitus.MethodsA total of 170 type 2 diabetes patients treated with sitagliptin ...
Eun Yeong Choe +10 more
doaj +1 more source
Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial [PDF]
, 2017 Objectives: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
Bolli, Geremia B. +7 more
core +2 more sources
Archives of Medical Science, 2019 Introduction Dipeptidyl peptidase-4 (DPP-4) inhibitors have various cellular effects that are associated with vascular protection. Here, we examined whether vildagliptin protected endothelial function in diabetic rats and explored the involved mechanism.
Qian Zhang +7 more
doaj +1 more source
Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice. [PDF]
PLoS ONE, 2013 AIM: Several recent reports have revealed that dipeptidyl peptidase (DPP)-4 inhibitors have suppressive effects on atherosclerosis in apolipoprotein E-null (Apoe (-/-)) mice. It remains to be seen, however, whether this effect stems from increased levels
Michishige Terasaki +11 more
doaj +1 more source
Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia [PDF]
, 2014 Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the BCR/ABL1 oncogene. Although mechanisms of BCR/ABL1-induced transformation are well-defined, little is known about effector-molecules contributing to malignant expansion and ...
Bilban, Martin +15 more
core +1 more source
DPP-4 inhibitor dose selection according to manufacturer specifications:A Contemporary Experience From UK General Practice [PDF]
, 2019 Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests.
Busse, Michael +5 more
core +1 more source